Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.
Identifieur interne : 004B15 ( PubMed/Curation ); précédent : 004B14; suivant : 004B16Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.
Auteurs : C G Goetz [États-Unis] ; G T Stebbins ; J A ThelenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Adult, Azepines (adverse effects), Azepines (therapeutic use), Dopamine Agents (adverse effects), Dopamine Agents (therapeutic use), Double-Blind Method, Humans, Male, Middle Aged, Neurologic Examination, Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Tourette Syndrome (drug therapy), Tourette Syndrome (physiopathology), Videotape Recording.
- MESH :
- chemical , adverse effects : Azepines, Dopamine Agents.
- chemical , drug effects : Receptors, Dopamine.
- chemical , physiology : Receptors, Dopamine.
- chemical , therapeutic use : Azepines, Dopamine Agents.
- drug therapy : Tourette Syndrome.
- physiopathology : Tourette Syndrome.
- Adult, Double-Blind Method, Humans, Male, Middle Aged, Neurologic Examination, Videotape Recording.
Abstract
Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double-blind, placebo-controlled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.
DOI: 10.1002/mds.870090306
PubMed: 7913738
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004B15
Links to Exploration step
pubmed:7913738Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.</title><author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C G" last="Goetz">C G Goetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Stebbins, G T" sort="Stebbins, G T" uniqKey="Stebbins G" first="G T" last="Stebbins">G T Stebbins</name></author><author><name sortKey="Thelen, J A" sort="Thelen, J A" uniqKey="Thelen J" first="J A" last="Thelen">J A Thelen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7913738</idno><idno type="pmid">7913738</idno><idno type="doi">10.1002/mds.870090306</idno><idno type="wicri:Area/PubMed/Corpus">004B15</idno><idno type="wicri:Area/PubMed/Curation">004B15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.</title><author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C G" last="Goetz">C G Goetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Stebbins, G T" sort="Stebbins, G T" uniqKey="Stebbins G" first="G T" last="Stebbins">G T Stebbins</name></author><author><name sortKey="Thelen, J A" sort="Thelen, J A" uniqKey="Thelen J" first="J A" last="Thelen">J A Thelen</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Azepines (adverse effects)</term><term>Azepines (therapeutic use)</term><term>Dopamine Agents (adverse effects)</term><term>Dopamine Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Tourette Syndrome (drug therapy)</term><term>Tourette Syndrome (physiopathology)</term><term>Videotape Recording</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Azepines</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azepines</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Videotape Recording</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double-blind, placebo-controlled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7913738</PMID><DateCreated><Year>1994</Year><Month>08</Month><Day>25</Day></DateCreated><DateCompleted><Year>1994</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>1994</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.</ArticleTitle><Pagination><MedlinePgn>315-7</MedlinePgn></Pagination><Abstract><AbstractText>Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double-blind, placebo-controlled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>G T</ForeName><Initials>GT</Initials></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7AM2J46Z1Y</RegistryNumber><NameOfSubstance UI="C024763">talipexole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001381">Azepines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014743">Videotape Recording</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7913738</ArticleId><ArticleId IdType="doi">10.1002/mds.870090306</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004B15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:7913738
|texte= Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:7913738" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |